liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry
Jagiellonian University.
Jagiellonian University.
Jagiellonian University.
Linköping University, Department of Medicine and Health Sciences, Cardiology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.ORCID iD: 0000-0002-9375-5087
Show others and affiliations
2010 (English)In: KARDIOLOGIA POLSKA, ISSN 0022-9032, Vol. 68, no 5, 539-545 p.Article in journal (Refereed) Published
Abstract [en]

Background: Primary percutaneous coronary intervention (PCI) is the preferred method of reperfusion in patients with ST elevation myocardial infarction (STEMI). Abciximab is a well established adjunct to primary PCI. The proper timing of abciximab administration in STEMI patients has been investigated in randomised trials, registries and metanalysis, providing conflicting results. Methods: Consecutive data on STEMI patients, transferred for primary PCI in hospital/ambulance STEMI networks between November 2005 and January 2007, from 15 PCI centres in seven European countries was gathered together for a one-year long-term clinical observation (93% rate of completeness). Results: Data from 1,650 patients was collected in the EUROTRANSFER Registry. Abciximab was administered to 1,086 patients (66%), 727 patients received early (at least 30 minutes prior to first balloon inflation) abciximab (EA), and another 359 patients received late abcixirnab (LA). One year mortality was 5.8% in the EA group vs 10.3% with LA (p = 0.007). Adjustment for propensity score methods for EA administration did not change the results, still providing a favourable outcome for the EA group (p = 0.004). It was also revealed that only a minority of patients (36%) were treated within the 90-minute recommended time window from first medical contact to PCI (and 60% for the 120-min time delay). Conclusions: Patients transferred for primary PCI in STEMI hospital networks showed lower rates of death in long-term one-year clinical follow-up when treatment with abciximab was started early.

Place, publisher, year, edition, pages
Polish Cardiac Society / TERMEDIA , 2010. Vol. 68, no 5, 539-545 p.
Keyword [en]
myocardial infarction, percutaneous coronary intervention, abciximab, registry
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-57391ISI: 000278398600006PubMedID: 20491016OAI: diva2:325559
Available from: 2010-06-18 Created: 2010-06-18 Last updated: 2013-09-11

Open Access in DiVA

No full text

Other links

PubMedLink to journal

Search in DiVA

By author/editor
Janzon, Magnus
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 20 hits
ReferencesLink to record
Permanent link

Direct link